PHILLIPS LYTLE LAUNCHES PSYCHEDELICS & MENTAL HEALTH THERAPIES PRACTICE
BUFFALO, N.Y., Aug. 18, 2022 /PRNewswire/ -- Phillips Lytle LLP announced the launch of its Psychedelics & Mental Health Therapies Practice Team, which is uniquely equipped to help pharmaceutical companies, research organizations and other stakeholders navigate the evolving legal and regulatory landscape related to the development, approval and use of psychedelic medications. Phillips Lytle Special Counsel Kyle W. Mack, who holds a doctorate in pharmacy, and Lisa L. Smith, a partner with the firm and co-leader of the firm's Life Sciences & Health Effects Team, will lead the practice, bringing together scientist-attorneys and experienced litigators to support clients that are driving innovation in mental health treatments.
- Promising research in psychedelics as a mental health treatment accelerates growth of industry in need of legal counsel.
- Phillips Lytle is a leader nationally and in New York State in forming a multidisciplinary practice to serve the psychedelics industry.
- "We are at the beginning of a revolution in how mental health conditions are medically treated.
- Psychedelics present a new potential path to relief for patients who continue to struggle with mental health conditions despite conventional therapies," he added.